Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Bristol Myers Squibb Stock a Buy?

TheMotleyFool

0 0

Bristol Myers Squibb (NYSE: BMY) stock hasn't performed very well so far this year. The company will soon face generic competition for top-selling Revlimid. However, it also has several newer drugs and pipeline candidates with great potential. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not the big pharma stock is a buy.

Source Fool.com

Like: 0

BMY

Share